Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome

OBJECTIVES: Mutations affecting the TMEM173 gene cause STING-associated vasculopathy with onset in infancy (SAVI). No standard immunosuppressive treatment approach is able to control disease progression in patients with SAVI. We studied the efficacy and safety of targeting type I IFN signaling with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Immunol
Egile Nagusiak: Volpi, Stefano, Insalaco, Antonella, Caorsi, Roberta, Santori, Elettra, Messia, Virginia, Sacco, Oliviero, Terheggen-Lagro, Suzanne, Cardinale, Fabio, Scarselli, Alessia, Pastorino, Claudia, Moneta, Gianmarco, Cangemi, Giuliana, Passarelli, Chiara, Ricci, Margherita, Girosi, Donata, Derchi, Maria, Bocca, Paola, Diociaiuti, Andrea, El Hachem, May, Cancrini, Caterina, Tomà, Paolo, Granata, Claudio, Ravelli, Angelo, Candotti, Fabio, Picco, Paolo, DeBenedetti, Fabrizio, Gattorno, Marco
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7086512/
https://ncbi.nlm.nih.gov/pubmed/31144250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-019-00645-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak